Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review
Issued Date
2023-02-01
Resource Type
ISSN
17449979
eISSN
17449987
Scopus ID
2-s2.0-85130713768
Pubmed ID
35583180
Journal Title
Therapeutic Apheresis and Dialysis
Volume
27
Issue
1
Start Page
159
End Page
169
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutic Apheresis and Dialysis Vol.27 No.1 (2023) , 159-169
Suggested Citation
Naciri Bennani H., Banza A.T., Terrec F., Noble J., Jouve T., Motte L., Malvezzi P., Rostaing L. Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review. Therapeutic Apheresis and Dialysis Vol.27 No.1 (2023) , 159-169. 169. doi:10.1111/1744-9987.13885 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85135
Title
Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review
Author's Affiliation
Other Contributor(s)
Abstract
Background: Cryoglobulinemia is defined as the presence of an abnormal immunoglobulin that may be responsible for vasculitis of small-caliber vessels. Apheresis can be used in order to temporarily eliminate circulating cryoglobulins. The aim of this study was to assess the effectiveness of apheresis (double-filtration plasmapheresis-DFPP-) in symptomatic and/or severe cryoglobulinemias. Methods: Four male patients presenting cryoglobulinemic vasculitis and who received DFPP sessions were included. Results: Their mean age was 57 ± 15 years. One patient had hepatitis-C virus (HCV)-related cryoglobulinemia and the other three patients were carriers of an IgM Kappa monoclonal gammopathy. Mean duration of follow-up was 15 ± 2 months. DFPP allowed healing of ulcerative skin lesions in the first patient and remission of nephrotic syndrome in the other patients after a median of 6(5–10) sessions. Conclusion: DFPP can be used safely in cryoglobulinemic-vasculitis and can be considered early to achieve a faster and sustained clinical-biological response.